Clin2
NCT06174753Possibly a fitRecruiting

Dapagliflozin for large heart attacks (STEMI)

ST Elevation Myocardial InfarctionMyocardial Infarction

Treatments studied

Part of Heart & circulation clinical trials.

This trial tests whether a diabetes drug called dapagliflozin can help people recover from a major heart attack (STEMI). You may qualify if you had a large heart attack within the last 12 hours and have not had a heart attack before.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
256 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Chest pain lasting at least 30 minutes
  • Chest pain started within the last 12 hours
  • High-risk ECG pattern (large ST elevation in many leads)
  • No prior heart attack
  • No type 1 diabetes
  • No kidney failure (eGFR above 30)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06286878Recruiting· Phase 2/Phase 3
Dapagliflozin after a heart attack: recovery study

This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.

São Paulo, São Paulo
NCT06009874Recruiting
SGLT2 inhibitor early after heart attack to protect the heart

This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.

Shibīn al Kawm, Menofia
NCT07295223Recruiting· Phase 3
GLP-1 and SGLT2 drugs for heart attack recovery

This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.

León, Guanajuato
NCT05764057Recruiting· Phase 3
Dapagliflozin to help the heart heal after a heart attack

This trial tests whether dapagliflozin (a diabetes medicine also used for heart protection) can reduce harmful heart “remodeling” after an acute heart attack. It may help your heart function and structure recover over the following 6 months.

Paris
NCT07741890Not yet recruiting· Phase 2
Dapagliflozin for chest pain with non-blocked arteries

This trial tests a medicine called dapagliflozin to see if it can reduce chest pain in people whose heart arteries are not blocked but still have reduced blood flow to the heart muscle. It may help improve symptoms and quality of life.

NCT07403955Not yet recruiting
Study of Dapagliflozin for heart function in acute heart failure

This trial tests if dapagliflozin, a medication usually used for diabetes, can help people with acute heart failure recover heart function. If you are in the hospital for heart failure, this study will check if the drug improves how your heart squeezes.

Hear when a new ST Elevation Myocardial Infarction trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.